0001019687-12-000790.txt : 20120306 0001019687-12-000790.hdr.sgml : 20120306 20120305185357 ACCESSION NUMBER: 0001019687-12-000790 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20120305 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20120306 DATE AS OF CHANGE: 20120305 FILER: COMPANY DATA: COMPANY CONFORMED NAME: SIMULATIONS PLUS INC CENTRAL INDEX KEY: 0001023459 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-COMPUTER INTEGRATED SYSTEMS DESIGN [7373] IRS NUMBER: 954595609 FISCAL YEAR END: 0831 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-32046 FILM NUMBER: 12668227 BUSINESS ADDRESS: STREET 1: 42505 10TH STREET WEST STREET 2: * CITY: LANCASTER STATE: CA ZIP: 93534-7059 BUSINESS PHONE: 661-723-7723 MAIL ADDRESS: STREET 1: 42505 10TH STREET WEST CITY: LANCASTER STATE: CA ZIP: 93534-7059 8-K 1 simulation_8k-030512.htm FORM 8K simulation_8k-030512.htm


­­­­­­­­­­­­­­­­­­­­
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934


March 5, 2011
(Date of the earliest event reported)


Simulations Plus, Inc.
(Exact name of registrant as specified in its charter)

 
California    001-32046   95-4595609
(State or other jurisdiction of incorporation)   (Commission File Number)    (I.R.S. Employer Identification No.)
                                                                                                    

42505 10th Street West, Lancaster, California 93534-7059
(Address of principal executive offices) (Zip Code)


661-723-7723
Registrant's telephone number, including area code


Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o
Soliciting material pursuant to Rule 14z-12 under Exchange Act (17 CFR 240.14a-12)

o
Pre-commencement communications pursuant to Rule 14d-2(b) under Exchange Act (17 CFR 240.14d-2(b))

o
Pre-commencement communications pursuant to Rule 13e-4(c) under Exchange Act (17 CFR 240.13e-4(c))




 
 
 
 
 
Item 8.01       Other Events

On March 5, 2012, Simulations Plus, Inc., a California corporation (the "Company"), issued a press release announcing preliminary revenues for its second fiscal quarter of fiscal year 2012 ended February 29, 2012. The press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

This report on Form 8-K (the "Report"), including the disclosures set forth herein, contains certain forward-looking statements that involve substantial risks and uncertainties. When used herein, the terms "anticipates," "expects," "estimates," "believes" and similar expressions, as they relate to us or our management, are intended to identify such forward-looking statements.

Forward-looking statements in this Report or hereafter, including in other publicly available documents filed with the Securities and Exchange Commission (the "Commission"), reports to the stockholders of Simulations Plus, Inc., a California corporation (the "Company" or "us," "our" or "we") and other publicly available statements issued or released by us involve known and unknown risks, uncertainties and other factors which could cause our actual results, performance (financial or operating) or achievements to differ from the future results, performance (financial or operating) or achievements expressed or implied by such forward-looking statements. Such future results are based upon management's best estimates based upon current conditions and the most recent results of operations. These risks include, but are not limited to, the risks set forth herein and in such other documents filed with the Commission, each of which could adversely affect our business and the accuracy of the forward-looking statements contained herein. Our actual results, performance or achievements may differ materially from those expressed or implied by such forward-looking statements.


Item 9.01       Financial Statements and Exhibits
 
 
(c)           Exhibits
 
 
99.1  
Press Release dated March 5, 2012.


 
 
 

 
 
 

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
 
 
 
 
 
  SIMULATIONS PLUS, INC.  
       
Dated: March 5, 2012
By:
/s/ Momoko Beran  
    Momoko Beran   
    Chief Financial Officer   

 
 
 
 
 
 
 

                                                                                                           


                                                                                                                                                                                                                                                                                                                                 
EX-99.1 2 simulations_8kex99-1.htm PRESS RELEASE simulations_8kex99-1.htm

Exhibit 99.1
 
Simulations Plus
Integrating Science and Software

For Further Information:
Simulations Plus, Inc.
42505 10th Street West
Lancaster, CA 93534-7059

 
CONTACT:
Simulations Plus Investor Relations   Hayden IR
Ms. Renée Bouché   Mr. Cameron Donahue
661-723-7723   651-653-1854
renee@simulations-plus.com   cameron@haydenir.com
 
For Immediate Release:
March 5, 2012

Simulations Plus Reports Record Second Quarter FY2012 Preliminary Revenues

Net sales increase to new record for any quarter of $2.789 million, up 24% sequentially and 6.4% compared to 2QFY11

LANCASTER, CA, March 5, 2012 – Simulations Plus, Inc. (NASDAQ: SLP), a leading provider of simulation and modeling software for pharmaceutical discovery and development, today reported preliminary revenues for its second quarter of fiscal year 2012 ended February 29, 2012 (2QFY12). Results below are reported for continuing operations (without the discontinued operations of the Company’s former Words+ subsidiary), except as noted.

2QFY12 highlights compared with 2QFY11:
·  
This was the Company’s 18th consecutive profitable quarter and the 40th of the last 42 quarters.
·  
Preliminary revenues increased to $2.789 million from $2.622 million – a new record for any quarter.
·  
Approximately 15% of revenues came from new software licenses.
·  
Approximately 4% of revenues came from consulting studies.
·  
Cash as of February 29, 2012 was approximately $13.3 million, up 52% from $8.8 million on February 28, 2011. On March 1, the Company paid approximately $0.8 million for its first ongoing dividend of $0.05 per share per quarter, leaving approximately $12.5 million.

Walt Woltosz, chairman and chief executive officer of Simulations Plus, said: “Fiscal year 2012 continues our trend of growth and profitability with a new record for any quarter in our second quarter, layering on top of our announced record first quarter revenue. We are focused on increasing our market penetration and delivering accelerating operating leverage as incremental top-line growth drives faster bottom-line increases. The continued adoption of simulation and modeling software, both by regulatory agencies and the pharmaceutical industry, will drive additional opportunities for our best-in-class product offerings supported by our strong capital structure with cash now approximately $12.5 million and no debt.”
 
-more-

 
 

 
About Simulations Plus, Inc.

Simulations Plus, Inc., is a premier developer of groundbreaking drug discovery and development simulation software, which is licensed to and used in the conduct of drug research by major pharmaceutical and biotechnology companies worldwide. For more information, visit our Web site at www.simulations-plus.com.

Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995 – With the exception of historical information, the matters discussed in this press release are forward-looking statements that involve a number of risks and uncertainties.  Words like “believe,” “expect” and “anticipate” mean that these are our best estimates as of this writing, but that there can be no assurances that expected or anticipated results or events will actually take place, so our actual future results could differ significantly from those statements.  Factors that could cause or contribute to such differences include, but are not limited to: our ability to maintain our competitive advantages, acceptance of new software and improved versions of our existing software by our customers, the general economics of the pharmaceutical industry, our ability to finance growth, our ability to continue to attract and retain highly qualified technical staff, our ability to identify and close acquisitions on terms favorable to the Company, and a sustainable market.  Further information on our risk factors is contained in our quarterly and annual reports as filed with the U.S. Securities and Exchange Commission.

###